UPC Analytics
ENDE
Overview · Filed:

UPC_APP_43889/2024

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Procedural & sub-applicationsOther ProceduralCourt of AppealGeneric application
  • 2024-07-30Procedural onlyappeal_decisionGeneric application

    The Court of Appeal rejected Alexion Pharmaceuticals' request to expedite the appeal against the Hamburg Local Division's refusal to grant provisional measures against Amgen, holding that the circumstances were not sufficiently urgent to justify shortening the time period for the respondents to lodge their statement of response.